Furthermore, there is a major focus on gene therapy, such as onasemnogen abeparvovec, a viral vector with DNA encoding for the survival of motor neuron (SMN) protein, which has been approved by the FDA for treatment of SMA type 1 (50). This evidence concerns the gene SMN1 and spinal muscular atrophy, type 1.